BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uriarte-Pinto M, Escolano-Pueyo Á, Gimeno-Ballester V, Pascual-Martínez O, Abad-Sazatornil MR, Agustín-Ferrández MJ. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer. Int J Clin Pharm 2016;38:446-53. [PMID: 26951122 DOI: 10.1007/s11096-016-0278-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer (Dove Med Press) 2019;11:29-42. [PMID: 30643452 DOI: 10.2147/BCTT.S179750] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Zhao M, Ding XF, Shen JY, Zhang XP, Ding XW, Xu B. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. J Zhejiang Univ Sci B 2017;18:15-26. [PMID: 28070993 DOI: 10.1631/jzus.B1600303] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
3 Sousa I, Rodrigues F, Prazeres H, Lima RT, Soares P. Liposomal therapies in oncology: does one size fit all? Cancer Chemother Pharmacol 2018;82:741-55. [DOI: 10.1007/s00280-018-3668-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
4 Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, Kong LQ. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. Ther Clin Risk Manag 2018;14:1789-97. [PMID: 30310287 DOI: 10.2147/TCRM.S176214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen S, Song Z, Feng R. Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel. ACAMC 2020;20:2169-89. [DOI: 10.2174/1871520620666200719001038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wu YT, Xu Z, Arshad B, Wu JS, Zhang K, Wu H, Li X, Li H, Li YC, Wang ZL, Wu KN, Kong LQ. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials. J Cancer 2018;9:3168-76. [PMID: 30210640 DOI: 10.7150/jca.24701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]